Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaratumab in Advanced GIST
NCT01316263Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2011
- Primary completion
- May 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of olaratumab in gastrointestinal stromal tumor (GIST), sponsored by Eli Lilly and Company. Started Aug 2011; status: terminated.
02
Drugs
olaratumab
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT01316263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01316263.